Tebipenem is an orally available carbapenem antibiotic, shows broad-spectrum activity against Gram-positive and -negative bacteria, except for Pseudomonas aeruginosa.
Tebipenem exhibits slow tight-binding inhibition at low micromolar concentrations versus the chromogenic substrate nitrocefin, and apparent Km and kcat values of 0.8 μM and 0.03 min-1, respectively[1]. Tebipenem shows potent activity against B. pseudomallei, with MIC50 and MIC90 values of both 2 mg/L[2]. Tebipenem shows good activity against S. pneumoniae, with the MIC range of ≤0.25 μg/mL in all of the S. pneumoniae isolates[3].
References:
[1]. Hazra S, et al. Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosis. Biochemistry. 2014 Jun 10;53(22):3671-8.
[2]. Seenama C, et al. In vitro activity of tebipenem against Burkholderia pseudomallei. Int J Antimicrob Agents. 2013 Oct;42(4):375.
[3]. Li H, et al. In vitro antibacterial activities of two novel oral antibiotics, tebipenem and cefditoren, and other comparators against community-acquired respiratory tract infection-associated bacterial pathogens: A multicentre study in China. Int J Antimicrob Agents. 2014 Jan;43(1):92-3.